Janus Henderson Group
MAZE

Janus Henderson Group’s Maze Therapeutics MAZE Stock Holding History

Janus Henderson Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.3M Sell
2,858,876
-283,711
-9% -$12.5M 0.04% 309
2025
Q4 		$130M Buy
3,142,587
+2,390,713
+318% +$82.2M 0.06% 240
2025
Q3 		$19.5M Sell
751,874
-649,386
-46% -$11M 0.01% 628
2025
Q2 		$17.3M Buy
1,401,260
+154,890
+12% +$1.61M 0.01% 593
2025
Q1 		$14.3M Buy
+1,246,370
New +$15M 0.01% 637

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Janus Henderson Group's MAZE Position: Q1 2026 in Review

Janus Henderson Group reduced its Maze Therapeutics (MAZE) stake by 9% in Q1 2026, selling an estimated $12.5M and leaving 2,858,876 shares worth $85.3M. The position accounts for 0.04% of the portfolio, ranked #309.

Janus Henderson Group first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $130M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Janus Henderson Group held 2,858,876 shares of Maze Therapeutics worth $85.3M as of Q1 2026.
  • Janus Henderson Group sold 283,711 Maze Therapeutics shares in Q1 2026, an estimated $12.5M.
  • Maze Therapeutics made up 0.04% of Janus Henderson Group's portfolio in Q1 2026, its #309 holding.
  • Janus Henderson Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Janus Henderson Group's Maze Therapeutics position peaked at $130M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.